|
|
|
|
||
Strong Buy
Great News-Up big time in after market hoursTech. U.S. Markets closed S&P 500. 2,815.44 +10.07(+0.36%) Dow 30. 25,717.46 +91.87(+0.36%) Nasdaq. 7,669.17 +25.79(+0.34%) Russell 2000. 1,535.10 +12.87(+0.85%) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY GlobeNewswire•March 28, 2019 -- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response -- -- Significant Inhibition of Radiographic Progression Demonstrated with Both Doses of Filgotinib versus Placebo -- -- Safety Profile of Filgotinib Consistent with Previously Reported Results -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019; 22.00 CET; regulated information - Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis. FINCH 1 evaluated filgotinib versus adalimumab or placebo, on a stable background dose of methotrexate in patients with prior inadequate response to methotrexate. The study achieved its primary endpoint for both doses of filgotinib in the proportion of patients achieving an American College of Rheumatology 20 percent response (ACR20) compared to placebo at Week 12. |
return to message board, top of board |